Rabbit Recombinant Monoclonal HLA DMB antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Transfected cell line - Human, Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
IHC-P | IP | WB | Flow Cyt (Intra) | |
---|---|---|---|---|
Human | Not recommended | Not recommended | Tested | Tested |
Transfected cell line - Human | Not recommended | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line - Human | Dilution info 1/10000 | Notes - |
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/500 | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line - Human | Dilution info - | Notes - |
Select an associated product type
Plays a critical role in catalyzing the release of class II-associated invariant chain peptide (CLIP) from newly synthesized MHC class II molecules and freeing the peptide binding site for acquisition of antigenic peptides. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO.
DMB, RING7, HLA-DMB, MHC class II antigen DMB, Really interesting new gene 7 protein
Rabbit Recombinant Monoclonal HLA DMB antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Transfected cell line - Human, Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-HLA DMB antibody [EPR7981] (ab133640) at 1/1000 dilution
Lane 1: Raji lysate at 10 µg
Lane 2: Daudi lysate at 10 µg
Lane 3: Human spleen lysate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 29 kDa
Intracellular Flow Cytometry analysis of permeabilized Raji cells labelling HLA DMB with ab133640 at 1/100 dilution (red). Rabbit IgG (negative control) shown in green.
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody.
Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 was used as a loading control.
All lanes: Western blot - Anti-HLA DMB antibody [EPR7981] (ab133640) at 1/10000 dilution
Lane 1: 293T (Human embryonic kidney epithelial cell) whole cell lysate with blank vector transfected at 15 µg
Lane 2: 293T (Human embryonic kidney epithelial cell) whole cell lysate with His tagged HLA DMB expression vector transfected at 15 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 29 kDa
Observed band size: 29 kDa
Exposure time: 1s
Image collected and cropped by CiteAb under a CC-BY license from the publication
HLA DMB western blot using anti-HLA DMB antibody [EPR7981] ab133640. Publication image and figure legend from Liu, B., Feng, S., et al., 2019, BMC Nephrol, PubMed 31113397.
ab133640 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab133640 please see the product overview.
Upregulation of HLA-DMB expression on HPMCs after exposure to PYS or to HPG at day 3 and day 7. The mean of fluorescence intensity (MFI) of HLA-DMB staining on HPMCs after repeating exposure to PYS or to HPG at day 3 and day 7 compared to untreated control at day 0 (as a baseline) was measured by using flow cytometric analysis. The ratio of MFI on treated cells to its baseline was presented as fold change of HLA-DMB expression. a Data were presented as a typical histogram of HLA-DMB stain (solid line) in each group compared to the baseline (MFI: 126, dotted line), showing the fold change of HLA-DMB expression. b Data were presented as mean ± SD of four separate experiments (n = 4). p = 0.0036 (PYS vs. HPG, two-way ANOVA). *p = 0.0011 (PYS: day 3 vs. day 7, t-test). **p = 0.0032 (HPG: day 3 vs. day 7, t-test). (C) The total cellular levels of HLA-DMB staining on HPMCs after repeating exposure to PYS or to HPG at day 3 and day 7 compared to untreated control at day 0 were determined by Western blot analysis. Equal amount of protein (100 to 150 μg) extracted from whole cell pellets was fractioned by 10% of SDS-PAGE, and HLA-DMB protein bands were identified based on specifically binding of anti-HLA-DMB antibody, and their molecular size (26–28 kDa) (upper panel). The protein content in each sample was confirmed by re-probing the blot with anti-GAPDH antibody (middle panel) and was measured by densitometry. Imaging data are a representative of three separate experiments. The ratio of HLA-DMB band to GAPDH band from the same sample on the same blot was presented (bottom panel)
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com